Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Harvard Bioscience Inc’s stock clocked out at $0.45, down -0.66% from its previous closing price of $0.45. In other words, the price has decreased by -$0.66 from its previous closing price. On the day, 1.39 million shares were traded. HBIO stock price reached its highest trading level at $0.476 during the session, while it also had its lowest trading level at $0.42.
Ratios:
To gain a deeper understanding of HBIO’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.59 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 52.47. For the most recent quarter (mrq), Quick Ratio is recorded 0.40 and its Current Ratio is at 0.81. In the meantime, Its Debt-to-Equity ratio is 3.01 whereas as Long-Term Debt/Eq ratio is at 0.49.
On March 10, 2023, The Benchmark Company Upgraded its rating to Buy which previously was Speculative Buy and also upped its target price recommendation from $3 to $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HBIO now has a Market Capitalization of 19935956 and an Enterprise Value of 58683060. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.22 while its Price-to-Book (P/B) ratio in mrq is 1.34. Its current Enterprise Value per Revenue stands at 0.642 whereas that against EBITDA is 19.759.
Stock Price History:
The Beta on a monthly basis for HBIO is 1.54, which has changed by -0.85623 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, HBIO has reached a high of $3.48, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is 3.81%, while the 200-Day Moving Average is calculated to be -65.07%.
Shares Statistics:
It appears that HBIO traded 12.39M shares on average per day over the past three months and 1079330 shares per day over the past ten days. A total of 44.21M shares are outstanding, with a floating share count of 37.41M. Insiders hold about 15.39% of the company’s shares, while institutions hold 58.44% stake in the company. Shares short for HBIO as of 1749772800 were 2831924 with a Short Ratio of 0.13, compared to 1747267200 on 1957393. Therefore, it implies a Short% of Shares Outstanding of 2831924 and a Short% of Float of 6.9299996.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Harvard Bioscience Inc (HBIO) is presently subject to a detailed evaluation by 2.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.01, with high estimates of $0.03 and low estimates of $0.0.
Analysts are recommending an EPS of between $0.05 and $0.02 for the fiscal current year, implying an average EPS of $0.04. EPS for the following year is $0.06, with 2.0 analysts recommending between $0.08 and $0.04.
Revenue Estimates
In the current quarter, 2 analysts expect revenue to total $18.75M. It ranges from a high estimate of $19.5M to a low estimate of $18M. As of the current estimate, Harvard Bioscience Inc’s year-ago sales were $23.1MFor the next quarter, 2 analysts are estimating revenue of $21.5M. There is a high estimate of $21.5M for the next quarter, whereas the lowest estimate is $21.5M.
A total of 2 analysts have provided revenue estimates for HBIO’s current fiscal year. The highest revenue estimate was $87M, while the lowest revenue estimate was $86M, resulting in an average revenue estimate of $86.5M. In the same quarter a year ago, actual revenue was $94.14MBased on 2 analysts’ estimates, the company’s revenue will be $95.15M in the next fiscal year. The high estimate is $95.8M and the low estimate is $94.5M.
